⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MBRX News
Moleculin Biotech, Inc.
Form 8-K
sec.gov
MBRX
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
globenewswire.com
MBRX
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
accessnewswire.com
AIM
AKTX
CNSP
DARE
NVNO
ERNA
GRI
MBRX
OTLK
Form 8-K
sec.gov
MBRX
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Announces Pricing of $9.3 Million Public Offering
globenewswire.com
MBRX
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
globenewswire.com
MBRX